Published on : Apr 22, 2015
The pharmaceutical sector is too unstable to predict. The medicines in development might not function as should, the U.S. FDA may not provide approval; and even after approved, it could do badly in the market.
Yet, many pharmaceutical enterprises are secured by patents, and those patents permit them to recoup their research and development investments and then some should they produce a winner. The sector is also loaded with mergers and acquisitions that can be beneficial for investors. The pharmaceutical firms’ deals are aggravated by the wish to beef up the pipelines of novel drugs and rationalize heavy research costs.
First one is Novo Nordisk A/S, a medical healthcare company, which is engaged in the discovery, development, production, and marketing of pharmaceutical products in the global arena. It operates in Biopharmaceuticals and Diabetes Care.
At the second position, it is Dr. Reddy's Laboratories Limited that operates as an incorporated pharmaceutical firm in India. It operates in Pharmaceutical Services, Global Generics, and Active Ingredients (PSAI), and Proprietary Products.
Last one is Jersey based Shire. Shire plc. is a biopharmaceutical firm. It researches, licenses, develops, manufactures, promotes, distributes, and trade pharmaceutical products together with its subsidiaries. The growth in the revenue generated is higher than the market’s average of 10.8% for the firm. Since the same quarter in the previous year, the revenues increased by 18.9%. The growth in the firm’s revenue appears to have assisted in boosting the earnings per share.